Cognitive Remediation Therapy for improving cognitive and emotional skills in schizophrenia
A Randomized Controlled EEG-GSR Study on the Effects of Cognitive Remediation Therapy on Neurophysiological and Emotional Regulation Markers in Schizophrenia
This study tests if Cognitive Remediation Therapy can help people with schizophrenia improve their thinking and emotional skills over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Beykoz University Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06936397 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of Cognitive Remediation Therapy (CRT) on cognitive and emotional functioning in individuals with schizophrenia. It involves a randomized controlled design with 60 participants, including 30 diagnosed with schizophrenia and 30 healthy controls. Participants with schizophrenia will receive CRT over 12 weeks, focusing on enhancing attention, memory, and emotional regulation through structured exercises. The study will utilize EEG and GSR measurements to assess changes in brain activity and emotional responses before and after the intervention.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 to 55 diagnosed with schizophrenia who are clinically stable and able to provide informed consent.
Not a fit: Patients with current or past substance use disorders, significant neurological illnesses, or those with severe cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly enhance cognitive and emotional functioning in patients with schizophrenia, leading to improved quality of life.
How similar studies have performed: Previous studies have shown promising results for cognitive remediation therapies in schizophrenia, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria (Schizophrenia Group): * Diagnosed with schizophrenia according to DSM-5 criteria * Age between 18 and 55 years * Clinically stable (no hospitalization or medication change within 1 month) * Minimum primary school education * Able to provide informed consent * Right-handed (for EEG protocol consistency) Inclusion Criteria (Healthy Control Group): * No history of psychiatric or neurological disorders * Age- and gender-matched to schizophrenia group * No current medication affecting CNS * Able to provide informed consent * Right-handed Exclusion Criteria (Both Groups): * Current or past substance use disorder (within the past year) * Comorbid neurological illness (e.g., epilepsy, traumatic brain injury) * Current use of benzodiazepines or medications that significantly affect cognitive function * Intellectual disability or MoCA score \< 20 * Visual or hearing impairments that could interfere with task performance * Participation in a psychological intervention in the last 3 months
Where this trial is running
Istanbul
- Beykoz University — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Metin Çınaroğlu, Phd — İstanbul Nişantaşı University
- Study coordinator: Eda Yılmazer, Phd
- Email: edayilmazer@beykoz.edu.tr
- Phone: 00905322575880
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.